Diacerhein attenuates the inflammatory response and improves survival in a model of severe sepsis

Critical Care

Volumn 16, Issue 4, 2012, Pages

  Calisto, Kelly L ^a   Camacho, Angélica C ^a   Mittestainer, Francine C ^a   Carvalho, Bruno M ^a   Guadagnini, Dioze ^a   Carvalheira, José B ^a   Saad, Mario J ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CASPASE 3; CYTOKINE; DIACEREIN; GLUCOSE; I KAPPA B ALPHA; I KAPPA B KINASE; INITIATION FACTOR 2ALPHA; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; ANTHRAQUINONE DERIVATIVE; ANTIINFLAMMATORY AGENT; GLUCOSE BLOOD LEVEL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG SAFETY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; IMMUNOMODULATION; INFLAMMATION; INSULIN RESISTANCE; LIVER; MALE; MUSCLE TISSUE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; UPREGULATION; ANIMAL; BLOOD; METABOLISM; PATHOPHYSIOLOGY; SKELETAL MUSCLE; WISTAR RAT;

ADIPOSE TISSUE; ANIMALS; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; CYTOKINES; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MUSCLE, SKELETAL; RATS, WISTAR; SEPSIS; SIGNAL TRANSDUCTION;

EID: 84864949789     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11478     Document Type: Article

References (66)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. 10.1097/00003246-199206000-00025, 1597042, American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.
2. Almog Y. Statins, inflammation, and sepsis: hypothesis. Chest 2003, 124:740-743. 10.1378/chest.124.2.740, 12907568.
3. Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004, 30:748-756. 10.1007/s00134-004-2167-y, 14991101.
4. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care?. J Clin Invest 2004, 114:1187-1195. 524243, 15520847.
5. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000, 85:2970-2973. 10.1210/jc.85.8.2970, 10946914.
6. Aljada A, Friedman J, Ghanim H, Mohanty P, Hofmeyer D, Chaudhuri A, Dandona P. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism 2006, 55:1177-1185. 10.1016/j.metabol.2006.04.016, 16919536.
7. Maitra SR, Wojnar MM, Lang CH. Alterations in tissue glucose uptake during the hyperglycemic and hypoglycemic phases of sepsis. Shock 2000, 13:379-385. 10.1097/00024382-200005000-00006, 10807013.
8. Kyle UG, Coss Bu JA, Kennedy CE, Jefferson LS. Organ dysfunction is associated with hyperglycemia in critically ill children. Intensive Care Med 2010, 36:312-320. 10.1007/s00134-009-1703-1, 19882139.
9. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801. 10.1172/JCI29069, 1483173, 16823477.
10. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 1999, 284:309-313. 10.1126/science.284.5412.309, 10195894.
11. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999, 340:207-214. 10.1056/NEJM199901213400307, 9895401.
12. American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. From the bench to the bedside: the future of sepsis research. Chest 1997, 111:744-753.
13. Smith GN, Myers SL, Brandt KD, Mickler EA, Albrecht ME. Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum 1999, 42:545-554. 10.1002/1529-0131(199904)42:3<545::AID-ANR20>3.0.CO;2-4, 10088778.
14. Moore AR, Greenslade KJ, Alam CA, Willoughby DA. Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage 1998, 6:19-23. 10.1053/joca.1997.0088, 9616435.
15. Nicolas P, Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet 1998, 35:347-359. 10.2165/00003088-199835050-00002, 9839088.
16. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG, Di Battista JA, Martel-Pelletier J. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998, 41:1275-1286. 10.1002/1529-0131(199807)41:7<1275::AID-ART19>3.0.CO;2-T, 9663486.
17. Pelletier JP, Lajeunesse D, Reboul P, Mineau F, Fernandes JC, Sabouret P, Martel-Pelletier J. Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol 2001, 28:814-824.
18. Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol 1998, 25:2417-2424.
19. Boittin M, Redini F, Loyau G, Pujol JP. [Effect of diacerhein (ART 50) on the matrix synthesis and collagenase secretion by cultured joint chondrocytes in rabbits]. Rev Rhum Ed Fr 1993, 60:68S-76S.
20. Del Rosso M, Fibbi G, Magnelli L, Pucci M, Dini G, Grappone C, Caldini R, Serni U, Colombo F, Borella F. Modulation of urokinase receptors on human synovial cells and osteoarthritic chondrocytes by diacetylrhein. Int J Tissue React 1990, 12:91-100.
21. Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol 1998, 25:753-762.
22. Mian M, Brunelleschi S, Tarli S, Rubino A, Benetti D, Fantozzi R, Zilletti L. Rhein: an anthraquinone that modulates superoxide anion production from human neutrophils. J Pharm Pharmacol 1987, 39:845-847.
23. de Isla N, Charif N, Stoltz JF. Are FoxO transcription factors implicated in osteoarthritis? Influence of diacerhein. Biomed Mater Eng 2010, 20:227-233.
24. Mendes AF, Caramona MM, de Carvalho AP, Lopes MC. Diacerhein and rhein prevent interleukin-1beta-induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-alpha. Pharmacol Toxicol 2002, 91:22-28. 10.1034/j.1600-0773.2002.910104.x, 12193257.
25. Lin YJ, Zhen YS. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice. Anticancer Drugs 2009, 20:65-72. 10.1097/CAD.0b013e3283182913, 19343002.
26. Delpino A, Paggi MG, Gentile PF, Castiglione S, Bruno T, Benass M, Floridi A. Protein synthetic activity and adenylate energy charge in Rhein-treated cultured human glioma cells. Cancer Biochem Biophys 1992, 12:241-252.
27. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 2009, 4:31-36. 2754226, 19131954.
28. Tamura T, Shirai T, Kosaka N, Ohmori K, Takafumi N. Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharmacol 2002, 448:81-87. 10.1016/S0014-2999(02)01898-8, 12126975.
29. Carvalho-Filho MA, Ueno M, Hirabara SM, Seabra AB, Carvalheira JB, de Oliveira MG, Velloso LA, Curi R, Saad MJ. S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance. Diabetes 2005, 54:959-967. 10.2337/diabetes.54.4.959, 15793233.
30. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63. 10.2337/diacare.23.1.57, 10857969.
31. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, Araujo EP, Vassallo J, Curi R, Velloso LA, Saad MJ. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56:1986-1998. 10.2337/db06-1595, 17519423.
32. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683. 10.1146/annurev.immunol.14.1.649, 8717528.
33. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006, 444:860-867. 10.1038/nature05485, 17167474.
34. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25:4-7. 10.1016/j.it.2003.10.013, 14698276.
35. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11:191-198. 10.1038/nm1185, 15685170.
36. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336. 10.1038/nature01137, 12447443.
37. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, Ye J. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 2002, 277:48115-48121. 10.1074/jbc.M209459200, 12351658.
38. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80. 10.1038/23948, 9817203.
39. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001, 108:437-446. 209353, 11489937.
40. Arcaroli J, Silva E, Maloney JP, He Q, Svetkauskaite D, Murphy JR, Abraham E. Variant IRAK-1 haplotype is associated with increased nuclear factor-kappaB activation and worse outcomes in sepsis. Am J Respir Crit Care Med 2006, 173:1335-1341. 10.1164/rccm.200603-341OC, 2662973, 16528020.
41. Arnalich F, Garcia-Palomero E, Lopez J, Jimenez M, Madero R, Renart J, Vazquez JJ, Montiel C. Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis. Infect Immun 2000, 68:1942-1945. 10.1128/IAI.68.4.1942-1945.2000, 97370, 10722586.
42. Yang KY, Arcaroli JJ, Abraham E. Early alterations in neutrophil activation are associated with outcome in acute lung injury. Am J Respir Crit Care Med 2003, 167:1567-1574. 10.1164/rccm.200207-664OC, 12626346.
43. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996, 87:13-20. 10.1016/S0092-8674(00)81318-5, 8858144.
44. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111:1448-1454. 10.1161/01.CIR.0000158483.13093.9D, 15781756.
45. Marshall JC. Sepsis: current status, future prospects. Curr Opin Crit Care 2004, 10:250-264. 10.1097/01.ccx.0000134877.60312.f3, 15258497.
46. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, Bottiger BW, Stern DM, Waldherr R, Saeger HD, Ziegler R, Bierhaus A, Martin E, Nawroth PP. Role of NFkappaB in the mortality of sepsis. J Clin Invest 1997, 100:972-985. 10.1172/JCI119648, 508272, 9276714.
47. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis?. Lancet Infect Dis 2006, 6:242-248. 10.1016/S1473-3099(06)70439-X, 16554249.
48. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119. 1087185, 15864338.
49. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461. 10.1126/science.1103160, 15486293.
50. Boden G, Duan X, Homko C, Molina EJ, Song W, Perez O, Cheung P, Merali S. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 2008, 57:2438-2444. 10.2337/db08-0604, 2518495, 18567819.
51. Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M, Ye J. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol 2004, 18:2024-2034. 10.1210/me.2003-0383, 15143153.
52. Hung JH, Su IJ, Lei HY, Wang HC, Lin WC, Chang WT, Huang W, Chang WC, Chang YS, Chen CC, Lai MD. Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem 2004, 279:46384-46392. 10.1074/jbc.M403568200, 15319438.
53. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367. 10.1056/NEJMoa011300, 11794168.
54. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002, 277:32124-32132. 10.1074/jbc.M203298200, 12052830.
55. Schabbauer G, Tencati M, Pedersen B, Pawlinski R, Mackman N. PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice. Arterioscler Thromb Vasc Biol 2004, 24:1963-1969. 10.1161/01.ATV.0000143096.15099.ce, 15319270.
56. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?. J Clin Endocrinol Metab 2001, 86:3257-3265. 10.1210/jc.86.7.3257, 11443198.
57. Dandona P, Ghanim H, Bandyopadhyay A, Korzeniewski K, Ling Sia C, Dhindsa S, Chaudhuri A. Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans. Diabetes Care 2010, 33:2416-2423. 10.2337/dc10-0929, 2963505, 20699433.
58. Kidd LB, Schabbauer GA, Luyendyk JP, Holscher TD, Tilley RE, Tencati M, Mackman N. Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther 2008, 326:348-353. 10.1124/jpet.108.138891, 2836781, 18445780.
59. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999, 27:1230-1251. 10.1097/00003246-199907000-00002, 10446814.
60. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6:813-822. 10.1038/nri1943, 17039247.
61. Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, Tattevin P, Thomas R, Fauchet R, Drenou B. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002, 18:487-494. 10.1097/00024382-200212000-00001, 12462554.
62. Park YC, Lee CH, Kang HS, Chung HT, Kim HD. Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, enhances LPS-induced NO production from murine peritoneal macrophages. Biochem Biophys Res Commun 1997, 240:692-696. 10.1006/bbrc.1997.7722, 9398628.
63. Kim I, Oh JL, Ryu YS, So JN, Sessa WC, Walsh K, Koh GY. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J 2002, 16:126-128.
64. Zhao L, Lee JY, Hwang DH. The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-kappaB pathway. Biochem Pharmacol 2008, 75:1515-1525. 10.1016/j.bcp.2007.12.014, 18243161.
65. Fruman DA, Snapper SB, Yballe CM, Davidson L, Yu JY, Alt FW, Cantley LC. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science 1999, 283:393-397. 10.1126/science.283.5400.393, 9888855.
66. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125-139. 10.1056/NEJMoa070716, 18184958.